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ESMO Clinical Practice Guidelines:
development, implementation and
dissemination
introduction
Clinical practice guidelines (CPGs) are defined as ‘systemically
developed statements to assist practitioner and patient
decisions about appropriate health care for specific clinical
circumstances’.
The main purposes of GPGs are: (i) to improve the quality of
patient care and health care outcomes; (ii) to make clinical
decisions more transparent; (iii) to promote efficient use of
resources; (iv) to provide guidance for involved stakeholders
(health professionals, patients, industry, health care providers
and policies makers); (v) to support quality control.
The original idea for the creation of the ESMO CPGs came in
1998 and in 1999 the ESMO Guidelines Task Force was
constituted. The structure of the ESMO Guidelines Working
Group consists of an Editorial Board (four members), of 10
subject editors responsible for each tumour site, of 100
authors and co-authors as well as of 150 reviewers, five for each
guideline.
development of ESMO CPGs
ESMO CPGs are produced through a narrative literature search
and are based on a multidisciplinary approach. All members of
the ESMO Guidelines Working Group (editors, subject editors,
authors, reviewers) are participating in the development
process. Table 1 demonstrates the ESMO Guidelines
development process.
In addition, during the last couple of years several ESMO
CPGs have been produced through consensus conferences or
meetings sponsored by ESMO or in collaboration with other
scientific bodies. Similar activities are planned for the years
2010 and 2011 (Table 2).
In total, ESMO have published 54 CPGs covering almost all
tumour types as well as various other topics, i.e. therapeutic use
of growth factors or anti-emetics or management of
paraneoplastic syndromes.
implementation of ESMO CPGs
ESMO CPGs are properly and effectively implemented and are
adequately incorporated into routine clinical practice. This
implementation facilitates knowledge uptake and leads to better
patient-focused care.
The targeted health professionals for ESMO CPGs are mainly
medical oncologists. ESMO CPGs are annually published in the
Annals of Oncology and they are also available on the ESMO
Website. The numbers of downloads from the Oxford Journals
usage statistics extracted data for the period May 2007–
September 2009 showed an exponential increase. The last
estimation for the 5 months between May 2009 and September
2009 was 89 604 hits, i.e. almost double compared with the
previous 6 months.
Table 1. ESMO Guidelines development process
ESMO GLWG Selects topics
Subject editors (SEs) Invite authors
Authors Send manuscript to SEs
Subject editors Select reviewers
Reviewers Return manuscript to SEs
Subject editors Send manuscript to Editors for first ‘make
decision’ process
Editors Return manuscript to SEs
Subject editors Notify authors
Authors Accept final comments
Subject editors Send manuscript to Editor for final approval
Editors Make final decision
Table 2. Consensus meeting-derived ESMO CPGS
Date Event Venue Funded by
October 2007 Soft tissue sarcomas and GIST Lugano, Switzerland Conticanet
May 2008 Testicular cancer Munich, Germany ESMO (EIS)
May 2009 Communication skills Kappel am Albis, Switzerland Swiss Cancer League
June 2009 Anti-emetics Perugia, Italy MASCC/ESMO
November 2009 Sarcomas (STS) Lugano, Switzerland Conticanet
November 2009 Sarcomas (bone) Lugano, Switzerland Eurobonet
May 2010 Lung cancer Lugano, Switzerland ESMO, San Salvatore Foundation
September 2010 Colorectal Barcelona, Spain ESMO
February 2011 Head and neck cancer Barcelona, Spain ESMO–ESTRO–EHNS
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Also, a questionnaire consisting of 10 questions assessing the
attitude of oncologists relating to ESMO CPGs was distributed
to the participants of ESMO Congresses and of Education
Conferences – Lugano (ECLU). From the analysis of the
questionnaire it was encouraging to find that ESMO CPGs have
been successfully recognized by European and non-European
oncologists.
dissemination of ESMO CPGs
During the last several years ESMO CPGs have been
disseminated various different ways such as.
(i) The interactive ESMO Guideline session conducting
during the ESMO Congresses with case presentation
and discussion by using the ESMO CPGs. Each session
is evaluated through electronic vote. Up to now, ESMO
has organized six interactive sessions, where the average
score has been increased from 3.78 to 4.48.
(ii) The translation of ESMO CPGs to other languages. So far,
ESMO guidelines have been translated into 13 different
languages.
(iii) The presentation of ESMO CPGs at international and
national congresses, conferences, symposia and workshops.
(iv) The publication of related articles or editorials in scientific
journals or newsletters.
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